Tg54531 is a transgenic mouse with transmembrane human TNF deregulated expression resulting in the spontaneous development of arthritis pathology that closely resembles human rheumatoid arthritis.
The mice develop arthritis with 100% penetrance and provide a fast in-vivo model for evaluating human therapeutics targeting rheumatoid arthritis.
The Tg5453 mouse model was successfully used in establishing the therapeutic efficacy of Remicade®, the first anti-TNF therapeutic to be successfully applied in the clinic, and is currently used for screening anti-rheumatoid candidate drugs.
Representative graph of the progression of the in vivo arthritic score in Tg5453 animals untreated or treated with commercially available anti-hTNF therapeutics.
Download the whitepaper to learn more on:
- The disease model
- Study design
- Routes of administration
- Validation data
- Analysis options